HUM vs LCTX · P/E 39, rev $117.76B vs rev $9.5M
Humana Inc (HUM) versus Lineage Cell Therapeutics Inc (LCTX) — a side-by-side from cached financials, not a winner call.
Humana Inc (HUM) is a healthcare plans company listed on NYSE.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
Latest reported HUM revenue for 2024-12-31 was $117.76B. Net income was $1.21B. Revenue was up 10.7% from 2023-12-31 to 2024-12-31. HUM currently screens at market cap $43.46B and trailing P/E 38.6.
Latest reported LCTX revenue for 2024-12-31 was $9.5M. Net income was -$18.6M. Revenue was up 354.9% from 2023-12-31 to 2024-12-31. LCTX currently screens at market cap $213.6M.
HUM currently screens at market cap $43.46B and trailing P/E 38.6. LCTX currently screens at market cap $213.6M.
Not investment advice. Open the HUM and LCTX stock pages for the full models.
Not investment advice.